ALKERMES, INC.
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT03610048
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03577262
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
🇳🇱University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, Netherlands
🇳🇱VU Medical Center, Dept. Radiology and Nuclear Medicine, Amsterdam, Netherlands
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03345979
- Locations
- 🇺🇸
Alkermes Investigational Site, Richardson, Texas, United States
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
- Conditions
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 524
- Registration Number
- NCT03201757
- Locations
- 🇬🇧
Alkermes Investigational Site, Headington, United Kingdom
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT03188185
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
🇺🇸Alkermes Investigative Site, Bellevue, Washington, United States
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT03187769
- Locations
- 🇬🇧
Alkermes Investigational Site, Maidstone, United Kingdom
An Insulin Sensitivity Study in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02922426
- Locations
- 🇺🇸
Alkermes Investigational Site, Chula Vista, California, United States
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 266
- Registration Number
- NCT02873208
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
A Phase 1 Safety Study in Adults With Schizophrenia
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02804568
- Locations
- 🇺🇸
Alkermes Investigational Site, Dayton, Ohio, United States
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
- Conditions
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT02696434
- Locations
- 🇺🇸
John Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Neuroscience Research Institute, Inc., Winfield, Illinois, United States
🇺🇸Segal Institute for Clinical Research, Lauderhill, Florida, United States